NOTICE TO THE BAR

MULTICOUNTY LITIGATION - CONCLUSION OF LEVAQUIN® MCL

In accordance with the provisions of Court Rule 4:38A and Directive #02-19, "Multicounty Litigation Guidelines and Criteria for Designation (Revised)," a September 7, 2021 Notice sought comments on the recommendation by Superior Court Judge Bruce Kaplan for conclusion of the multicounty litigation designation of the Levaquin® state-court litigation. This Notice is to advise that the Supreme Court, having received no comments in objection, has acted on that recommendation and concluded the centralized management and treatment of Levaquin cases as an MCL.

The Court's November 29, 2021 Order is published with this notice. Both also are posted on the Judiciary's Internet Website at (www.njcourts.gov) in the MCL Information Center http://www.njcourts.gov/attorneys/mcl/index.html.

Questions may be directed to Melissa A. Czartoryski, Chief, Civil Court Programs, Civil Practice Division, Administrative Office of the Courts, Hughes Justice Complex, P.O. Box 981, Trenton, New Jersey 08625-0981; telephone (609) 815-2900 ext. 54900; email address: Melissa.Czartoryski@njcourts.gov

Glenn A. Grant, J.A.D.

Acting Administrative Director of the Courts

Dated: December 27, 2021

SUPREME COURT OF NEW JERSEY

The Supreme Court by Order dated June 16, 2009 designated all New Jersey

state court Levaquin® litigation as a mass tort (now multicounty litigation) and assigned

that litigation to Atlantic County. The Court reassigned the Levaquin® litigation to

Middlesex County by Order dated October 31, 2014, which Order has since been

amended as to the designated judge, including most recently by Order dated January

25, 2021.

It is ORDERED that, effective immediately, the designation of all New Jersey

state court Levaquin[®] litigation as multicounty litigation is hereby concluded.

For the Court,

Chief Justice

Dated: November 29, 2021